Tilray, Inc. (TLRY)
5.0500 +0.26 (5.43%)
Before hours: 7:27AM EDT
| Previous Close | 4.7500 |
| Open | 4.7000 |
| Bid | 5.0100 x 4000 |
| Ask | 5.0200 x 1800 |
| Day's Range | 4.6427 - 4.8900 |
| 52 Week Range | 2.4300 - 25.9500 |
| Volume | 4,146,554 |
| Avg. Volume | 5,969,861 |
| Market Cap | 609.183M |
| Beta (5Y Monthly) | 2.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.7290 |
| Earnings Date | Aug. 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.15 |
- Business Wire
Tilray Medical Cannabis Product Shows Promise Reducing Nausea and Vomiting Caused by Chemotherapy in World First Clinical Trial
Tilray announced preliminary results from a world-first clinical trial finding for chemotherapy induced nausea and vomiting.
- Motley Fool
These 2 Robinhood Stocks Are Down Around 15% This Month: Should You Buy the Dip?
There's often a lot of hype surrounding Robinhood stocks, and sometimes that can help carry share prices to astronomical heights. Tilray's stock is down 26% in September, and yet the company hasn't released any news since it reported its second-quarter results on Aug. 10. The Horizons Marijuana Life Sciences ETFÂ (OTC: HMLSF) is down 13% this month, a more modest decline than Tilray's. What's surprising is that the British Columbia-based company is coming off a decent quarter during which it reported sales of $50.4 million for the period ending June 30.
- Yahoo Finance Video
State ballot measures to legalize cannabis add $9B to U.S. market: RPT
John Kagia, New Frontier Data Cheif Knowledge Officer, joins Yahoo Finance's Zach Guzman to discuss the cannabis outlook amid COVID-19 and the 2020 Presidential election.
